Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001247446 | SCV001420868 | likely pathogenic | Joubert syndrome 20; Meckel syndrome, type 11 | 2024-06-25 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 2 of the TMEM231 gene. It does not directly change the encoded amino acid sequence of the TMEM231 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (no rsID available, gnomAD 0.03%). This variant has been observed in individual(s) with clinical features of Joubert syndrome (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 971624). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Fulgent Genetics, |
RCV001247446 | SCV005646220 | uncertain significance | Joubert syndrome 20; Meckel syndrome, type 11 | 2024-03-07 | criteria provided, single submitter | clinical testing |